CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...